SRRK insider trading
NasdaqGS HealthcareScholar Rock Holding Corp: insider trade history from SEC Form 4 filings.
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Company website: www.scholarrock.com
SRRK insider activity at a glance
FilingIQ tracks 411 insider transactions for SRRK in filings since May 31, 2018. The most recent transaction is dated Sep 24, 2026.
Across the full history, 26 open-market purchases
and 161 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SRRK insider trades is 52.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SRRK Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SRRK?
- FilingIQ tracks 411 Form 4 insider transactions for SRRK (Scholar Rock Holding Corp), covering filings from May 31, 2018 onwards. 2 of those are dated within the last 90 days.
- Are SRRK insiders net buyers or net sellers?
- Across the full Form 4 history for SRRK, 26 transactions (6%) were open-market purchases and 161 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SRRK insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SRRK in?
- Scholar Rock Holding Corp (SRRK) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.83B.
Methodology & sources
Every SRRK insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.